Bezlotoxumab
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Clostridium Difficile
Conditions
Clostridium Difficile
Trial Timeline
Aug 30, 2019 → May 15, 2022
NCT ID
NCT03937999About Bezlotoxumab
Bezlotoxumab is a approved stage product being developed by Merck for Clostridium Difficile. The current trial status is terminated. This product is registered under clinical trial identifier NCT03937999. Target conditions include Clostridium Difficile.
What happened to similar drugs?
8 of 20 similar drugs in Clostridium Difficile were approved
Approved (8) Terminated (4) Active (12)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04626947 | Approved | Terminated |
| NCT03937999 | Approved | Terminated |
| NCT03756454 | Approved | Terminated |
Competing Products
20 competing products in Clostridium Difficile